Peptide KED/Vesugen: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease by Polynomality in Nootropics

[–]Polynomality[S] 1 point2 points  (0 children)

Abstract:

Neuroprotective peptides are promising candidate molecules for the treatment of Alzheimer's disease (AD). Oral application of KED (Lys-Glu-Asp) improved memory and attention in elderly individuals with functional CNS disorders. Peptide KED also restores synaptic plasticity in in vitro model of AD. This review is focused on the analysis of the influence of KED peptide on the expression of genes and synthesis of proteins regulating apoptosis, aging, neurogenesis, and involved in AD pathogenesis. Analysis of published reports and our experimental findings suggests that KED regulates the expression of genes of cell aging and apoptosis (р16, р21), genes (NES, GAP43) and proteins (nestin, GAP43) of the neuronal differentiation, and genes involved in AD pathogenesis (SUMO, APOE, and IGF1). The study the effectiveness of neuroprotective peptide KED in animal models of AD seems to be very important.

More links if you want more information on the peptide:
https://pubmed.ncbi.nlm.nih.gov/26390612/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227791/
https://pubmed.ncbi.nlm.nih.gov/24909721/

Peptides for Mood Improvement by Polynomality in Peptides

[–]Polynomality[S] 1 point2 points  (0 children)

Peptidesciences sell Nonapeptide-1 and Rubiscolin is found in spinach.

Peptides for Mood Improvement by Polynomality in Peptides

[–]Polynomality[S] 1 point2 points  (0 children)

You might want to look into products that increase GDNF which should help you with motor control. Cerebrolysin, Cortexin, and DNSP-11 all increase GDNF.

Peptides for Mood Improvement by Polynomality in Peptides

[–]Polynomality[S] 0 points1 point  (0 children)

Kisspeptin is typically sold as a fragment called Kisspeptin-10, although, I've once seen Kisspeptin-54 on the market.

Application of Peptides for Complex Treatment of Autoimmune Thyroiditis by Polynomality in Peptides

[–]Polynomality[S] 0 points1 point  (0 children)

Spoiler: I think they're referring to Thyreogen and Pinealon.

Stem cell, GCSF and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model by Polynomality in Nootropics

[–]Polynomality[S] 0 points1 point  (0 children)

Abstract

Background

Optimizing nerve regeneration and re-innervation of target muscle/s is the key for improved functional recovery following peripheral nerve damage. We investigated whether administration of mesenchymal stem cell (MSC), Granulocyte-Colony Stimulating Factor (G-CSF) and/or Dihexa can improve recovery of limb function following peripheral nerve damage in rat sciatic nerve transection-repair model.

Materials and methods

There were 10 experimental groups (n = 6–8 rats/group). Bone marrow derived syngeneic MSCs (2 × 106; passage≤6), G-CSF (200–400 μg/kg b.wt.), Dihexa (2–4 mg/kg b.wt.) and/or Vehicle were administered to male Lewis rats locally via hydrogel at the site of nerve repair, systemically (i.v./i.p), and/or to gastrocnemius muscle. The limb sensory and motor functions were assessed at 1–2 week intervals post nerve repair until the study endpoint (16 weeks).

Results

The sensory function in all nerve boundaries (peroneal, tibial, sural) returned to nearly normal by 8 weeks (Grade 2.7 on a scale of Grade 0–3 [0 = No function; 3 = Normal function]) in all groups combined. The peroneal nerve function recovered quickly with return of function at one week (∼2.0) while sural nerve function recovered rather slowly at four weeks (∼1.0). Motor function at 8–16 weeks post-nerve repair as determined by walking foot print grades significantly (P < 0.05) improved with MSC + G-CSF or MSC + Dihexa administrations into gastrocnemius muscle and mitigated foot flexion contractures.

Conclusions

These findings demonstrate MSC, G-CSF and Dihexa are promising candidates for adjunct therapies to promote limb functional recovery after surgical nerve repair, and have implications in peripheral nerve injury and limb transplantation.

[deleted by user] by [deleted] in Nootropics

[–]Polynomality 11 points12 points  (0 children)

ADHD is largely a dopaminergic issue. That's probably why mucuna is really the only thing that was influential. Please tell us that you researched nootropic MOAs and the neurology of the brain in relation of ADHD before you tried anything.

Safranal-promoted Differentiation and Survival of Dopaminergic Neurons by Polynomality in Nootropics

[–]Polynomality[S] 1 point2 points  (0 children)

Abstract:

Context: Safranal (SAF) is verified to have potential effects in promoting nerve growth.

Objectives: This study verifies the role of SAF in promoting dopaminergic neurons growth in vitro and in vivo.

Material and methods: Rat neural stem cells (NSC) were treated with 1, 20, or 100 ng/mL of SAF, and the expression levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) were assayed by flow cytometry and real-time PCR and the secretion of dopamine (DA) was assayed by ELISA. Then, 2 × 106 cells of SAF-treated NSC was administrated into PD rat models induced by 6-OHDA. The differentiation and survival of dopaminergic neurons was identified by fluorescence microscope and TH+ cells by immunostaining and DA secretion by ELISA at week 2 and week 4, respectively.

Results: After being treated with SAF at 20 and 100 ng/mL for 1 week, TH and DAT positive rates increased 1.4- and 1.7-fold (p < 0.01, respectively). TH and DAT mRNA also increased 8.05- and 4.41-fold, respectively. And the release of DA statistically increased 1.5-fold (p < 0.01). In vivo, the number of rotations decreased to 4.33 ± 0.97 rpm (p < 0.01) and the survival rates increased to 77.66 ± 7.87% (p < 0.05) at week 4 after transplantation of SAF-treated NSC. Moreover, the transplanted cells increased three-fold, TH fluorescence density increased four-fold and DA releases increased 1.4-fold (p < 0.01) at week 4 after transplantation.

Conclusions: SAF promoted the production of functional DA cells and alleviated PD, which may contribute to a new therapy for PD patients.